Characterization of HIV-1 Nucleoside-Modified mRNA Vaccines in Rabbits and Rhesus Macaques

Antibody neutralization and escape by HIV-1

Wei, X., Decker, J. M., Wang, S., Hui, H., Kappes, J. C., Wu, X., Salazar-Gonzalez, J. F., Salazar, M. G., Kilby, J. M., Saag, M. S., et al. (2003) · Nature · doi:10.1038/nature01470 · Cited by 2,421 · see citing works

Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection

Keele, B. F., Giorgi, E. E., Salazar-Gonzalez, J. F., Decker, J. M., Pham, K. T., Salazar, M. G., Sun, C., Grayson, T. B., Wang, S., Li, H., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802203105 · Cited by 1,913 · see citing works

T follicular helper cell differentiation, function, and roles in disease

Crotty, S. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.004 · Cited by 1,847 · see citing works

Broad neutralization coverage of HIV by multiple highly potent antibodies

Walker, L. M., Huber, M., Doores, K. J., Falkowska, E., Pejchal, R., Julien, J.-P., Wang, S.-K., Ramos, A., Chan-Hui, P.-Y., Moyle, M., et al. (2011) · Nature · doi:10.1038/nature10373 · Cited by 1,480 · see citing works

Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01

Zhou, T., Georgiev, I. S., Wu, X., Yang, Z., Dai, K., Finzi, A., Kwon, Y. D., Scheid, J. F., Shi, W., Xu, L., et al. (2010) · Science · doi:10.1126/science.1192819 · Cited by 1,132 · see citing works

Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1

Trkola, A., Purtscher, M., Muster, T., Ballaun, C., Buchacher, A., Sullivan, N. J., Srinivasan, K., Sodroski, J., Moore, J. P., & Katinger, H. W. D. (1996) · Journal of Virology · doi:10.1128/jvi.70.2.1100-1108.1996 · Cited by 1,115 · see citing works

Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes

Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014 · see citing works

Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus

Liao, H., Lynch, R. M., Zhou, T., Gao, F., Alam, S. M., Boyd, S. D., Fire, A. Z., Roskin, K. M., Schramm, C. A., Zhang, Z., et al. (2013) · Nature · doi:10.1038/nature12053 · Cited by 987 · see citing works

Modified mRNA vaccines protect against zika virus infection

Richner, J. M., Himansu, S., Dowd, K. A., Butler, S. L., Salazar, V., Fox, J. M., Julander, J. G., Tang, W. W., Shresta, S., Pierson, T. C., et al. (2017) · Cell · doi:10.1016/j.cell.2017.02.017 · Cited by 909 · see citing works

Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination

Pardi, N., Hogan, M. J., Pelc, R. S., Muramatsu, H., Andersen, H., DeMaso, C. R., Dowd, K. A., Sutherland, L. L., Scearce, R. M., Parks, R., et al. (2017) · Nature · doi:10.1038/nature21428 · Cited by 884 · see citing works

Cardiolipin Polyspecific Autoreactivity in Two Broadly Neutralizing HIV-1 Antibodies

Haynes, B. F., Fleming, J., Clair, E. W. S., Katinger, H., Stiegler, G. M., Kunert, R., Robinson, J. E., Scearce, R. M., Plonk, K., Staats, H. F., et al. (2005) · Science · doi:10.1126/science.1111781 · Cited by 746 · see citing works

Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 influenza viruses

Bahl, K., Senn, J. J., Yuzhakov, O., Bulychev, A., Brito, L. A., Hassett, K. J., Laska, M. E., Smith, M., Almarsson, Ö., Thompson, J., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.03.035 · Cited by 642 · see citing works

Measuring HIV Neutralization in a Luciferase Reporter Gene Assay

Montefiori, D. C. (2009) · Methods in molecular biology · doi:10.1007/978-1-59745-170-3_26 · Cited by 585 · see citing works

Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses

Pardi, N., Hogan, M. J., Naradikian, M. S., Parkhouse, K., Cain, D. W., Jones, L., Moody, M. A., Verkerke, H. P., Myles, A., Willis, E., et al. (2018) · Journal of Experimental Medicine · doi:10.1084/jem.20171450 · Cited by 530 · see citing works

Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals

Thess, A., Grund, S., Mui, B. L., Hope, M. J., Baumhof, P., Fotin-Mleczek, M., & Schlake, T. (2015) · Molecular Therapy · doi:10.1038/mt.2015.103 · Cited by 513 · see citing works

Antibodies in HIV-1 Vaccine Development and Therapy

Klein, F., Mouquet, H., Dosenovic, P., Scheid, J. F., Scharf, L., & Nussenzweig, M. C. (2013) · Science · doi:10.1126/science.1241144 · Cited by 452 · see citing works

Vaccine-Induced Env V1-V2 IgG3 Correlates with Lower HIV-1 Infection Risk and Declines Soon After Vaccination

Yates, N. L., Liao, H., Fong, Y., deCamp, A. C., Vandergrift, N., Williams, W. T., Alam, S. M., Ferrari, G., Yang, Z., Seaton, K. E., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007730 · Cited by 449 · see citing works

Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin

Whittle, J. R. R., Zhang, R., Khurana, S., King, L. R., Manischewitz, J. F., Golding, H., Dormitzer, P. R., Haynes, B. F., Walter, E. B., Moody, M. A., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1111497108 · Cited by 439 · see citing works

Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation

Mouquet, H., Scheid, J. F., Zöller, M., Krogsgaard, M., Ott, R. G., Shukair, S. A., Artyomov, M. N., Pietzsch, J., Connors, M., Pereyra, F., et al. (2010) · Nature · doi:10.1038/nature09385 · Cited by 426 · see citing works

Broad and potent HIV-1 neutralization by a human antibody that binds the gp41–gp120 interface

Huang, J., Kang, B. H., Pancera, M., Lee, J. H., Tong, T., Feng, Y., Imamichi, H., Georgiev, I. S., Chuang, G., Druz, A., et al. (2014) · Nature · doi:10.1038/nature13601 · Cited by 421 · see citing works

Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2

Liao, H., Bonsignori, M., Alam, S. M., McLellan, J. S., Tomaras, G. D., Moody, M. A., Kozink, D. M., Hwang, K.-K., Chen, X., Tsao, C.-Y., et al. (2013) · Immunity · doi:10.1016/j.immuni.2012.11.011 · Cited by 378 · see citing works

Broadly Neutralizing HIV Antibodies Define a Glycan-Dependent Epitope on the Prefusion Conformation of gp41 on Cleaved Envelope Trimers

Falkowska, E., Le, K. M., Ramos, A. G., Doores, K. J., Lee, J. H., Blattner, C., Ramirez, A., Derking, R., van Gils, M. J., Liang, C. J., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.04.009 · Cited by 359 · see citing works

CD4 T follicular helper cell dynamics during SIV infection

Petrovas, C., Yamamoto, T., Gerner, M. Y., Boswell, K. L., Wloka, K., Smith, E. C., Ambrozak, D. R., Utay, N. S., Timmer, K. J., Sun, X., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci63039 · Cited by 317 · see citing works

HIV-1 Vaccines Based on Antibody Identification, B Cell Ontogeny, and Epitope Structure

Kwong, P. D., & Mascola, J. R. (2018) · Immunity · doi:10.1016/j.immuni.2018.04.029 · Cited by 306 · see citing works

CD4-Induced Conformational Changes in the Human Immunodeficiency Virus Type 1 gp120 Glycoprotein: Consequences for Virus Entry and Neutralization

Sullivan, N. R., Sun, Y., Sattentau, Q. J., Thali, M., Wu, D. T., Denisova, G. F., Gershoni, J. M., Robinson, J. E., Moore, J. P., & Sodroski, J. (1998) · Journal of Virology · doi:10.1128/jvi.72.6.4694-4703.1998 · Cited by 292 · see citing works

Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies

Pardi, N., Parkhouse, K., Kirkpatrick, E., McMahon, M., Zost, S. J., Mui, B. L., Tam, Y. K., Karikó, K., Barbosa, C. J., Madden, T. D., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05482-0 · Cited by 281 · see citing works

Broadly Neutralizing Antibody Responses in a Large Longitudinal Sub-Saharan HIV Primary Infection Cohort

Landais, E., Huang, X., Havenar‐Daughton, C., Murrell, B., Price, M. A., Wickramasinghe, L., Ramos, A. G., Bian, C. B., Simek, M. D., Allen, S. A., et al. (2016) · PLoS Pathogens · doi:10.1371/journal.ppat.1005369 · Cited by 265 · see citing works

Stable exposure of the coreceptor-binding site in a CD4-independent HIV-1 envelope protein

Hoffman, T. L., LaBranche, C. C., Zhang, W., Canziani, G., Robinson, J. E., CHAIKEN, I. M., Hoxie, J. A., & Doms, R. W. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.11.6359 · Cited by 263 · see citing works

Composition and Antigenic Effects of Individual Glycan Sites of a Trimeric HIV-1 Envelope Glycoprotein

Behrens, A., Vasiljević, S., Pritchard, L. K., Harvey, D. J., Andev, R. S., Krumm, S. A., Struwe, W. B., Cupo, A., Kumar, A., Zitzmann, N., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.02.058 · Cited by 251 · see citing works

Mechanism of Neutralization by the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01

Li, Y., O'Dell, S., Walker, L. M., Wu, X., Guenaga, J., Feng, Y., Schmidt, S. D., McKee, K., Louder, M. K., Ledgerwood, J. E., et al. (2011) · Journal of Virology · doi:10.1128/jvi.00754-11 · Cited by 235 · see citing works

Holes in the Glycan Shield of the Native HIV Envelope Are a Target of Trimer-Elicited Neutralizing Antibodies

McCoy, L. E., van Gils, M. J., Ozorowski, G., Messmer, T., Briney, B. S., Voss, J. E., Kulp, D. W., Macauley, M. S., Sok, D., Pauthner, M. G., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.07.074 · Cited by 230 · see citing works

Native‐like Env trimers as a platform for HIV ‐1 vaccine design

Sanders, R. W., & Moore, J. P. (2017) · Immunological Reviews · doi:10.1111/imr.12481 · Cited by 227 · see citing works

In Vitro Transcription of Long RNA Containing Modified Nucleosides

Pardi, N., Muramatsu, H., Weissman, D., & Karikó, K. (2012) · Methods in molecular biology · doi:10.1007/978-1-62703-260-5_2 · Cited by 204 · see citing works

High‐throughput quantitative analysis of HIV‐1 and SIV‐specific ADCC‐mediating antibody responses

Pollara, J., Hart, L., Brewer, F., Pickeral, J., Packard, B. Z., Hoxie, J. A., Komoriya, A., Ochsenbauer, C., Kappes, J. C., Roederer, M., et al. (2011) · Cytometry Part A · doi:10.1002/cyto.a.21084 · Cited by 202 · see citing works

Identification of Common Features in Prototype Broadly Neutralizing Antibodies to HIV Envelope V2 Apex to Facilitate Vaccine Design

Andrabi, R., Voss, J. E., Liang, C. J., Briney, B. S., McCoy, L. E., Wu, C., Wong, C., Poignard, P., & Burton, D. R. (2015) · Immunity · doi:10.1016/j.immuni.2015.10.014 · Cited by 193 · see citing works

Promiscuous Glycan Site Recognition by Antibodies to the High-Mannose Patch of gp120 Broadens Neutralization of HIV

Sok, D., Doores, K. J., Briney, B. S., Le, K. M., Saye-Francisco, K. L., Ramos, A. G., Kulp, D. W., Julien, J., Menis, S., Wickramasinghe, L., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008104 · Cited by 184 · see citing works

The Effects of Somatic Hypermutation on Neutralization and Binding in the PGT121 Family of Broadly Neutralizing HIV Antibodies

Sok, D., Laserson, U., Laserson, J., Liu, Y., Vigneault, F., Julien, J., Briney, B. S., Ramos, A. G., Saye-Francisco, K. L., Le, K. M., et al. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003754 · Cited by 183 · see citing works

HPLC purification of in vitro transcribed long RNA

Weissman, D., Pardi, N., Muramatsu, H., & Karikó, K. (2013) · Methods in molecular biology · doi:10.1007/978-1-62703-260-5_3 · Cited by 180 · see citing works

HIV-1 Vaccine-Induced C1 and V2 Env-Specific Antibodies Synergize for Increased Antiviral Activities

Pollara, J., Bonsignori, M., Moody, M. A., Liu, P., Alam, S. M., Hwang, K., Gurley, T. C., Kozink, D. M., Armand, L. C., Marshall, D. J., et al. (2014) · Journal of Virology · doi:10.1128/jvi.00156-14 · Cited by 178 · see citing works

Modified mRNA-Based Vaccines Elicit Robust Immune Responses and Protect Guinea Pigs From Ebola Virus Disease

Meyer, M., Huang, E., Yuzhakov, O., Ramanathan, P., Ciaramella, G., & Bukreyev, A. (2018) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix592 · Cited by 178 · see citing works

Tfh cells and HIV bnAbs, an immunodominance model of the HIV neutralizing antibody generation problem

Havenar‐Daughton, C., Lee, J. H., & Crotty, S. (2017) · Immunological Reviews · doi:10.1111/imr.12512 · Cited by 170 · see citing works

Polyreactivity and Autoreactivity among HIV-1 Antibodies

Liu, M., Yang, G., Wiehe, K. J., Nicely, N. I., Vandergrift, N., Rountree, W., Bonsignori, M., Alam, S. M., Gao, J., Haynes, B. F., et al. (2014) · Journal of Virology · doi:10.1128/jvi.02378-14 · Cited by 162 · see citing works

Neutralizing antibodies to HIV-1 induced by immunization

McCoy, L. E., & Weiss, R. A. (2013) · The Journal of Experimental Medicine · doi:10.1084/jem.20121827 · Cited by 137 · see citing works

Induction of robust B cell responses after influenza mRNA vaccination Is accompanied by circulating hemagglutinin-specific ICOS+ PD-1+ CXCR3+ T follicular helper cells

Lindgren, G., Ols, S., Liang, F., Thompson, E. A., Lin, A., Hellgren, F., Bahl, K., John, S., Yuzhakov, O., Hassett, K. J., et al. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01539 · Cited by 132 · see citing works

Effect of the cytoplasmic domain on antigenic characteristics of HIV-1 envelope glycoprotein

Chen, J., Kovacs, J. M., Peng, H., Rits‐Volloch, S., Lü, J., Park, D., Zablowsky, E., Seaman, M. S., & Chen, B. (2015) · Science · doi:10.1126/science.aaa9804 · Cited by 125 · see citing works

Quality and quantity of T FH cells are critical for broad antibody development in SHIV AD8 infection

Yamamoto, T., Lynch, R. M., Gautam, R., Matus‐Nicodemos, R., Schmidt, S. D., Boswell, K. L., Darko, S. W., Wong, P., Sheng, Z., Petrovas, C., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aab3964 · Cited by 117 · see citing works

Epitopes for neutralizing antibodies induced by HIV-1 envelope glycoprotein BG505 SOSIP trimers in rabbits and macaques

Klasse, P. J., Ketas, T. J., Cottrell, C. A., Ozorowski, G., Debnath, G., Camara, D., Francomano, E., Pugach, P., Ringe, R. P., LaBranche, C. C., et al. (2018) · PLoS Pathogens · doi:10.1371/journal.ppat.1006913 · Cited by 117 · see citing works

An autoreactive antibody from an SLE/HIV-1 individual broadly neutralizes HIV-1

Bonsignori, M., Wiehe, K. J., Grimm, S. K., Lynch, R. M., Yang, G., Kozink, D. M., Perrin, F., Cooper, A. J., Hwang, K., Chen, X., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci73441 · Cited by 87 · see citing works

Decreased T Follicular Regulatory Cell/T Follicular Helper Cell (TFH) in Simian Immunodeficiency Virus–Infected Rhesus Macaques May Contribute to Accumulation of TFH in Chronic Infection

Chowdhury, A., Estrada, P. M. D. R., Tharp, G. K., Trible, R. P., Amara, R. R., Chahroudi, A., Reyes‐Terán, G., Bosinger, S. E., & Silvestri, G. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402701 · Cited by 83 · see citing works

Residues in the gp41 Ectodomain Regulate HIV-1 Envelope Glycoprotein Conformational Transitions Induced by gp120-Directed Inhibitors

Pacheco, B., Alsahafi, N., Débbeche, O., Prévost, J., Ding, S., Chapleau, J.-P., Herschhorn, A., Madani, N., Princiotto, A. M., Melillo, B. N., et al. (2016) · Journal of Virology · doi:10.1128/jvi.02219-16 · Cited by 55 · see citing works

HIV-1 envelope glycoprotein immunogens to induce broadly neutralizing antibodies

Sliepen, K., & Sanders, R. W. (2015) · Expert Review of Vaccines · doi:10.1586/14760584.2016.1129905 · Cited by 47 · see citing works

The N276 Glycosylation Site Is Required for HIV-1 Neutralization by the CD4 Binding Site Specific HJ16 Monoclonal Antibody

Balla-Jhagjhoorsingh, S. S., Corti, D., Heyndríckx, L., Willems, E., Vereecken, K., Davis, D. A., & Vanham, G. L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0068863 · Cited by 46 · see citing works

Early Lymphoid Responses and Germinal Center Formation Correlate with Lower Viral Load Set Points and Better Prognosis of Simian Immunodeficiency Virus Infection

Hong, J. J., Amancha, P. K., Rogers, K. A., Courtney, C. L., Havenar‐Daughton, C., Crotty, S., Ansari, A. A., & Villinger, F. J. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1400749 · Cited by 44 · see citing works

Regulatory and Helper Follicular T Cells and Antibody Avidity to Simian Immunodeficiency Virus Glycoprotein 120

Blackburn, M. J., Ma, Z.-M., Caccuri, F., McKinnon, K. M., Schifanella, L., Guan, Y., Gorini, G., Venzon, D. J., Fenizia, C., Binello, N., et al. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402699 · Cited by 31 · see citing works

DNA Immunization for HIV Vaccine Development

Chen, Y., Wang, S., & Lu, S. (2014) · Vaccines · doi:10.3390/vaccines2010138 · Cited by 24 · see citing works

Integrity of Glycosylation Processing of a Glycan-Depleted Trimeric HIV-1 Immunogen Targeting Key B-Cell Lineages

Behrens, A., Kumar, A., Medina-Ramírez, M., Cupo, A., Marshall, K., Portillo, V. M. C., Harvey, D. J., Ozorowski, G., Zitzmann, N., Wilson, I. A., et al. (2018) · Journal of Proteome Research · doi:10.1021/acs.jproteome.7b00639 · Cited by 22 · see citing works

Evaluation of the contribution of the transmembrane region to the ectodomain conformation of the human immunodeficiency virus (HIV-1) envelope glycoprotein

Nguyen, H. T., Madani, N., Ding, H., Elder, E., Princiotto, A. M., Gu, C., Darby, P., Alin, J., Herschhorn, A., Kappes, J. C., et al. (2017) · Virology Journal · doi:10.1186/s12985-017-0704-x · Cited by 11 · see citing works

COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses

Sahin, U., Muik, A., Derhovanessian, E., Vogler, I., Kranz, L. M., Vormehr, M., Baum, A., Pascal, K., Quandt, J., Maurus, D., et al. (2020) · Nature · doi:10.1038/s41586-020-2814-7 · Cited by 1,977 · see citing works

mRNA vaccines for infectious diseases: principles, delivery and clinical translation

Chaudhary, N., Weissman, D., & Whitehead, K. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00283-5 · Cited by 1,555 · see citing works

BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans

Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 845 · see citing works

Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses

Alameh, M.-G., Tombácz, I., Bettini, E., Lederer, K., Ndeupen, S., Sittplangkoon, C., Wilmore, J. R., Gaudette, B. T., Soliman, O. Y., Pine, M., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.11.001 · Cited by 775 · see citing works

BNT162b vaccines protect rhesus macaques from SARS-CoV-2

Vogel, A. B., Kanevsky, I., Che, Y., Swanson, K. A., Muik, A., Vormehr, M., Kranz, L. M., Walzer, K. C., Hein, S., Güler, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03275-y · Cited by 694 · see citing works

Advances in COVID-19 mRNA vaccine development

Fang, E., Liu, X., Li, M., Zhang, Z., Song, L., Zhu, B., Wu, X., Liu, J., Zhao, D., & Li, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00950-y · Cited by 601 · see citing works

Self-amplifying RNA vaccines for infectious diseases

Bloom, K., van den Berg, F., & Arbuthnot, P. (2021) · Gene Therapy · doi:10.1038/s41434-020-00204-y · Cited by 487 · see citing works

Lipid nanoparticle technology for therapeutic gene regulation in the liver

Witzigmann, D., Kulkarni, J. A., Leung, J., Chen, S., Cullis, P. R., & van der Meel, R. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.026 · Cited by 376 · see citing works

Three decades of messenger RNA vaccine development

Verbeke, R., Lentacker, I., De Smedt, S. C., & Dewitte, H. (2019) · Nano Today · doi:10.1016/j.nantod.2019.100766 · Cited by 342 · see citing works

Recent advances in mRNA-LNP therapeutics: immunological and pharmacological aspects

Kiaie, S. H., Zolbanin, N. M., Ahmadi, A., Bagherifar, R., Valizadeh, H., Kashanchi, F., & Jafari, R. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01478-7 · Cited by 261 · see citing works

Modified mRNA/lipid nanoparticle-based vaccines expressing respiratory syncytial virus F protein variants are immunogenic and protective in rodent models of RSV infection

Espeseth, A. S., Cejas, P. J., Citron, M. P., Wang, D., DiStefano, D. J., Callahan, C., Donnell, G. O., Galli, J. D., Swoyer, R., Touch, S., et al. (2020) · npj Vaccines · doi:10.1038/s41541-020-0163-z · Cited by 190 · see citing works

Nanotechnology-based mRNA vaccines

Chen, S., Huang, X., Xue, Y., Álvarez‐Benedicto, E., Shi, Y., Chen, W., Koo, S., Siegwart, D. J., Dong, Y., & Tao, W. (2023) · Nature Reviews Methods Primers · doi:10.1038/s43586-023-00246-7 · Cited by 172 · see citing works

A multiclade env–gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques

Zhang, P., Narayanan, E., Liu, Q., Tsybovsky, Y., Boswell, K. L., Ding, S., Hu, Z., Follmann, D. A., Lin, Y., Miao, H., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01574-5 · Cited by 164 · see citing works

A prefusion SARS-CoV-2 spike RNA vaccine is highly immunogenic and prevents lung infection in non-human primates

Vogel, A. B., Kanevsky, I., Che, Y., Swanson, K. A., Muik, A., Vormehr, M., Kranz, L. M., Walzer, K. C., Hein, S., Güler, A., et al. (2020) · doi:10.1101/2020.09.08.280818 · Cited by 126 · see citing works

Nanomedicine-Based Approaches for mRNA Delivery

Uchida, S., Perche, F., Pichon, C., & Cabral, H. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00618 · Cited by 139 · see citing works

Nanovaccine: an emerging strategy

Das, A., & Ali, N. (2021) · Expert Review of Vaccines · doi:10.1080/14760584.2021.1984890 · Cited by 131 · see citing works

Development and Delivery Systems of mRNA Vaccines

Liang, Y., Huang, L., & Liu, T. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.718753 · Cited by 125 · see citing works

A Dengue Virus Serotype 1 mRNA-LNP Vaccine Elicits Protective Immune Responses

Wollner, C. J., Richner, M., Hassert, M., Pinto, A. K., Brien, J. D., & Richner, J. M. (2021) · Journal of Virology · doi:10.1128/jvi.02482-20 · Cited by 119 · see citing works

Lipid Nanoparticle (LNP) Delivery Carrier-Assisted Targeted Controlled Release mRNA Vaccines in Tumor Immunity

Wu, L., Li, X., Qian, X., Wang, S., Liu, J., & Yan, J. (2024) · Vaccines · doi:10.3390/vaccines12020186 · Cited by 125 · see citing works

Screening for lipid nanoparticles that modulate the immune activity of helper T cells towards enhanced antitumour activity

Zhu, Y., Ma, J., Shen, R., Lin, J., Li, S., Lu, X., Stelzel, J. L., Kong, J., Cheng, L., Vuong, I., et al. (2023) · Nature Biomedical Engineering · doi:10.1038/s41551-023-01131-0 · Cited by 109 · see citing works

Current Developments and Challenges of mRNA Vaccines

Chen, J., Chen, J., & Xu, Q. (2022) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-110220-031722 · Cited by 106 · see citing works

Approved and marketed nanoparticles for disease targeting and applications in COVID-19

Abdellatif, A. A. H., & Alsowinea, A. F. (2021) · Nanotechnology Reviews · doi:10.1515/ntrev-2021-0115 · Cited by 101 · see citing works

Messenger RNA-Based Vaccines Against Infectious Diseases

Alameh, M.-G., Weissman, D., & Pardi, N. (2020) · Current Topics in Microbiology and Immunology · doi:10.1007/82_2020_202 · Cited by 96 · see citing works

Modification of Lipid-Based Nanoparticles: An Efficient Delivery System for Nucleic Acid-Based Immunotherapy

Zhang, C., Ma, Y., Zhang, J., Kuo, J. C., Zhang, Z., Xie, H., Zhu, J., & Liu, T. (2022) · Molecules · doi:10.3390/molecules27061943 · Cited by 93 · see citing works

Modified mRNA-LNP Vaccines Confer Protection against Experimental DENV-2 Infection in Mice

Zhang, M., Sun, J., Li, M., & Jin, X. (2020) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2020.07.013 · Cited by 90 · see citing works

Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates

Saunders, K. O., Pardi, N., Parks, R., Santra, S., Mu, Z., Sutherland, L. L., Scearce, R. M., Barr, M., Eaton, A., Hernandez, G. E., et al. (2021) · npj Vaccines · doi:10.1038/s41541-021-00307-6 · Cited by 90 · see citing works

Promising Extracellular Vesicle-Based Vaccines against Viruses, Including SARS-CoV-2

Šabanović, B., Piva, F., Cecati, M., & Giulietti, M. (2021) · Biology · doi:10.3390/biology10020094 · Cited by 82 · see citing works

Lipid Nanoparticle Delivery Systems to Enable mRNA-Based Therapeutics

Semple, S. C., Leone, R. D., Barbosa, C., Tam, Y. K., & Lin, P. J. C. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14020398 · Cited by 80 · see citing works

HIV mRNA Vaccines—Progress and Future Paths

Mu, Z., Haynes, B. F., & Cain, D. W. (2021) · Vaccines · doi:10.3390/vaccines9020134 · Cited by 80 · see citing works

mRNA Vaccines against SARS-CoV-2: Advantages and Caveats

Echaide, M., Chocarro, L., Bocanegra, A., Blanco, E., Kochan, G. T., & Escors, D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065944 · Cited by 82 · see citing works

Lipid Nanoparticles for Organ-Specific mRNA Therapeutic Delivery

Żak, M. M., & Zangi, L. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13101675 · Cited by 75 · see citing works

Immunogenicity generated by mRNA vaccine encoding VZV gE antigen is comparable to adjuvanted subunit vaccine and better than live attenuated vaccine in nonhuman primates

Monslow, M. A., Elbashir, S., Sullivan, N. L., Thiriot, D. S., Ahl, P., Smith, J., Miller, E., Cook, J., Cosmi, S., Thoryk, E., et al. (2020) · Vaccine · doi:10.1016/j.vaccine.2020.06.062 · Cited by 75 · see citing works

mRNA vaccines: Past, present, future

Karam, M., & Daoud, G. (2022) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2022.05.003 · Cited by 74 · see citing works

Nucleoside-Modified mRNA Vaccines Protect IFNAR –/– Mice against Crimean-Congo Hemorrhagic Fever Virus Infection

Appelberg, S., John, L., Pardi, N., Végvári, Á., Bereczky, S., Ahlén, G., Monteil, V., Abdurahman, S., Mikaeloff, F., Beattie, M., et al. (2021) · Journal of Virology · doi:10.1128/jvi.01568-21 · Cited by 66 · see citing works

mRNA vaccines: a new opportunity for malaria, tuberculosis and HIV

Matarazzo, L., & Bettencourt, P. J. G. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1172691 · Cited by 64 · see citing works

Development and applications of mRNA treatment based on lipid nanoparticles

Wang, Z., Ma, W., Fu, X., Qi, Y., Zhao, Y., & Zhang, S. (2023) · Biotechnology Advances · doi:10.1016/j.biotechadv.2023.108130 · Cited by 57 · see citing works

Vaccination with Messenger RNA: A Promising Alternative to DNA Vaccination.

Tombácz, I., Weissman, D., & Pardi, N. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-0872-2_2 · Cited by 43 · see citing works

Lipid nanoparticle-based mRNA candidates elicit potent T cell responses

Zeng, Y., Escalona-Rayo, O., Knol, R. A., Kros, A., & Slütter, B. (2022) · Biomaterials Science · doi:10.1039/d2bm01581a · Cited by 54 · see citing works

High‐Precision Synthesis of RNA‐Loaded Lipid Nanoparticles for Biomedical Applications

Seo, H., Jeon, L., Kwon, J., & Lee, H. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202203033 · Cited by 51 · see citing works

Pneumococcal Vaccines: Past Findings, Present Work, and Future Strategies

Oliveira, G. S., Oliveira, M. L. S., Miyaji, E. N., & Rodrigues, T. C. (2021) · Vaccines · doi:10.3390/vaccines9111338 · Cited by 49 · see citing works

Nanoparticles in clinical trials of COVID-19: An update

Rauf, A., Abu‐Izneid, T., Khalil, A. A., Hafeez, N., Olatunde, A., Rahman, M. M., Semwal, P., Al-Awthan, Y. S., Bahattab, O. S., Khan, I. N., et al. (2022) · International Journal of Surgery · doi:10.1016/j.ijsu.2022.106818 · Cited by 45 · see citing works

mRNA vaccination compared to infection elicits an IgG-predominant response with greater SARS-CoV-2 specificity and similar decrease in variant spike recognition

Röltgen, K., Nielsen, S. C. A., Arunachalam, P. S., Yang, F., Hoh, R. A., Wirz, O. F., Lee, A. S., Gao, F., Mallajosyula, V., Li, C., et al. (2021) · doi:10.1101/2021.04.05.21254952 · Cited by 45 · see citing works

mRNA Vaccines against Flaviviruses

Wollner, C. J., & Richner, J. M. (2021) · Vaccines · doi:10.3390/vaccines9020148 · Cited by 44 · see citing works

Engineered mRNA Delivery Systems for Biomedical Applications

Wang, J., Zhu, H., Gan, J., Liang, G., Li, L., & Zhao, Y. (2023) · Advanced Materials · doi:10.1002/adma.202308029 · Cited by 44 · see citing works

Lipid Nanoparticle-Based Delivery SystemA Competing Place for mRNA Vaccines

Zhang, X., Li, Y., & Zhou, Z. (2024) · ACS Omega · doi:10.1021/acsomega.3c08353 · Cited by 43 · see citing works

Synthesis of point-modified mRNA

Hertler, J., Slama, K., Schober, B., Özrendeci, Z., Marchand, V., Motorin, Y., & Helm, M. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac719 · Cited by 35 · see citing works

mRNA-based vaccine technology for HIV

Albert-Ludwigs-Universität Freiburg, G., Fortner, A., & Bucur, O. (2022) · Discoveries · doi:10.15190/d.2022.9 · Cited by 32 · see citing works

Advances in mRNA and other vaccines against MERS-CoV

Tai, W., Zhang, X., Yang, Y., Zhu, J., & Du, L. (2021) · Translational research · doi:10.1016/j.trsl.2021.11.007 · Cited by 32 · see citing works

Strategies for inducing effective neutralizing antibody responses against HIV-1

del Moral-Sánchez, I., & Sliepen, K. (2019) · Expert Review of Vaccines · doi:10.1080/14760584.2019.1690458 · Cited by 31 · see citing works

mRNA-Based Vaccines and Mode of Action

Gergen, J., & Petsch, B. (2020) · Current topics in microbiology and immunology · doi:10.1007/82_2020_230 · Cited by 32 · see citing works

mRNA-based HIV-1 vaccines

Ahmed, S., & Herschhorn, A. (2024) · Clinical Microbiology Reviews · doi:10.1128/cmr.00041-24 · Cited by 28 · see citing works

In the Era of mRNA Vaccines, Is There Any Hope for HIV Functional Cure?

Esteban, I., Pastor-Quiñones, C., Usero, L., Plana, M., García, F., & Leal, L. (2021) · Viruses · doi:10.3390/v13030501 · Cited by 26 · see citing works

Strategies for eliciting multiple lineages of broadly neutralizing antibodies to HIV by vaccination

Mu, Z., Haynes, B. F., & Cain, D. W. (2021) · Current Opinion in Virology · doi:10.1016/j.coviro.2021.09.015 · Cited by 23 · see citing works

HIV and Messenger RNA Vaccine

Khalid, K., Padda, J., Khedr, A., Ismail, D., Zubair, U., Al-Ewaidat, O. A., Padda, S., Cooper, A. C., & Jean-Charles, G. (2021) · Cureus · doi:10.7759/cureus.16197 · Cited by 23 · see citing works

DLin-MC3-Containing mRNA Lipid Nanoparticles Induce an Antibody Th2-Biased Immune Response Polarization in a Delivery Route-Dependent Manner in Mice

Yavuz, A., Coiffier, C., Garapon, C., Gürcan, S., Monge, C., Exposito, J., Arruda, D. C., & Verrier, B. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15031009 · Cited by 20 · see citing works

Functional and Highly Cross-Linkable HIV-1 Envelope Glycoproteins Enriched in a Pretriggered Conformation

Nguyen, H. T., Qualizza, A., Anang, S., Zhao, M., Zou, S., Zhou, R., Wang, Q., Zhang, S., Deshpande, A. A., Ding, H., et al. (2022) · Journal of Virology · doi:10.1128/jvi.01668-21 · Cited by 19 · see citing works

Off the beaten path: Novel mRNA-nanoformulations for therapeutic vaccination against HIV

D’haese, S., Lacroix, C., García, F., Plana, M., Ruță, S. M., Vanham, G. L., Verrier, B., & Aerts, J. L. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.11.009 · Cited by 18 · see citing works

Preclinical Assessment of a Gene Editing Approach in a Mouse Model of MNGIE

Parés, M., Fornaguera, C., Vila‐Julià, F., Oh, S., Fan, S. H. Y., Tam, Y. K., Comes, N., Vidal, F., Martí, R., Borrós, S., et al. (2021) · Human Gene Therapy · doi:10.1089/hum.2021.152 · Cited by 17 · see citing works

BNT162b vaccines are immunogenic and protect non-human primates against SARS-CoV-2Preprint

Vogel, A. B., Kanevsky, I., Che, Y., Swanson, K. A., Muik, A., Vormehr, M., Kranz, L. M., Walzer, K. C., Hein, S., Güler, A., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.12.11.421008 · Cited by 18 · see citing works

Designing novel multiepitope mRNA vaccine targeting Hendra virus (HeV): An integrative approach utilizing immunoinformatics, reverse vaccinology, and molecular dynamics simulation

Mahdeen, A. A., Hossain, I., Masum, M. H. U., Islam, M. S., & Rabbi, T. M. F. (2024) · PLoS ONE · doi:10.1371/journal.pone.0312239 · Cited by 17 · see citing works

Multivalent cytomegalovirus glycoprotein B nucleoside modified mRNA vaccines did not demonstrate a greater antibody breadth

Wang, H.-Y., Li, L., Nelson, C. S., Barfield, R., Valencia, S. M., Chan, C. C. W., Muramatsu, H., Lin, P. J. C., Pardi, N., An, Z., et al. (2024) · npj Vaccines · doi:10.1038/s41541-024-00821-3 · Cited by 15 · see citing works

The current and future role of nanovaccines in HIV-1 vaccine development

Karch, C. P., & Matyas, G. R. (2021) · Expert Review of Vaccines · doi:10.1080/14760584.2021.1945448 · Cited by 14 · see citing works

Recent Advances in Messenger Ribonucleic Acid (mRNA) Vaccines and Their Delivery Systems: A Review

Belay, W. Y., Nibret, G., & Aschale, Y. (2023) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s418314 · Cited by 16 · see citing works

Potent cancer therapy by liposome microstructure tailoring with active-to-passive targeting and shell-to-core thermosensitive features

Zhao, M., Zhu, X., Li, B., Yan, C., Wu, C., He, L., Cao, J., Lu, F., Chen, H., & Li, W. (2024) · Materials Today Bio · doi:10.1016/j.mtbio.2024.101035 · Cited by 13 · see citing works

mRNA vaccines against HIV : Hopes and challenges

Zubair, A., Ahmad, H., Arif, M. M., & Ali, M. (2025) · HIV Medicine · doi:10.1111/hiv.70024 · Cited by 14 · see citing works

mRNA lipid nanoparticles expressing cell-surface cleavage independent HIV Env trimers elicit autologous tier-2 neutralizing antibodies

Guenaga, J., Alirezaei, M., Feng, Y., Alameh, M., Lee, W.-H., Baboo, S., Cluff, J., Wilson, R., Bale, S., Ozorowski, G., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1426232 · Cited by 12 · see citing works

Nucleic Acid Vaccine Platform for DENGUE and ZIKA Flaviviruses

Mourosi, J. T., Awe, A., Jain, S., & Batra, H. (2022) · Vaccines · doi:10.3390/vaccines10060834 · Cited by 12 · see citing works

The legacy of mRNA engineering: A lineup of pioneers for the Nobel Prize

Janowski, M., & Andrzejewska, A. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.07.003 · Cited by 11 · see citing works

Research progress of mRNA vaccines for infectious diseases

Zhang, Z., Du, J., Zhang, D., Han, R., Wu, X., & Liang, Y. (2025) · European journal of medical research · doi:10.1186/s40001-025-03060-x · Cited by 16 · see citing works

RNA Through Time: From the Origin of Life to Therapeutic Frontiers in Transcriptomics and Epitranscriptional Medicine

Campos, C. M., Lanz‐Mendoza, H., Cime‐Castillo, J., Peralta-Zaragoza, Ó., & Madrid‐Marina, V. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26114964 · Cited by 9 · see citing works

mRNA Vaccine Mitigates SARS-CoV-2 Infections and COVID-19

Kackos, C. M., Surman, S. L., Jones, B. G., Sealy, R. E., Jeevan, T., Davitt, C. J. H., Pustylnikov, S., Darling, T. L., Boon, A. C. M., Hurwitz, J. L., et al. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.04240-22 · Cited by 9 · see citing works

The emergence of nanovaccines as a new paradigm in virological vaccinology: a review

Baruah, C., Das, P., Devi, P., Saikia, P. M., & Deka, B. (2023) · Exploration of Immunology · doi:10.37349/ei.2023.00107 · Cited by 8 · see citing works

Nano-vaccines for gene delivery against HIV-1 infection

Li, S., Zhang, M., Yuan, J., & Zhang, Y.-X. (2023) · Expert Review of Vaccines · doi:10.1080/14760584.2023.2193266 · Cited by 8 · see citing works

An immunoinformatics approach in designing high-coverage mRNA multi-epitope vaccine against multivariant SARS-CoV-2

Giri-Rachman, E. A., Kurnianti, A. M. F., Rizarullah, R., Setyadi, A. H., Artarini, A., Tan, M. I., Riani, C., Natalia, D., Aditama, R., & Nugrahapraja, H. (2025) · Journal of Genetic Engineering and Biotechnology · doi:10.1016/j.jgeb.2025.100524 · Cited by 9 · see citing works

Advanced Nanobiomedical Approaches to Combat Coronavirus Disease of 2019

Lutz, H., Popowski, K. D., Dinh, P., & Cheng, K. (2020) · Advanced NanoBiomed Research · doi:10.1002/anbr.202000063 · Cited by 7 · see citing works

A mRNA-LNP vaccine against Dengue Virus elicits robust, serotype-specific immunity

Wollner, C. J., Richner, M., Hassert, M. A., Pinto, A. K., Brien, J. D., & Richner, J. M. (2021) · doi:10.1101/2021.01.05.425517 · Cited by 6 · see citing works

mRNA technology for the prevention and treatment of HIV-1 infection

Chuang, L. I. U., Yaremenko, A. V., Li, X., You, X., Zhu, X., Liu, N., Chen, W., Kong, N., Xie, T., Gaiha, G. D., et al. (2026) · Nature Reviews Bioengineering · doi:10.1038/s44222-025-00387-2 · Cited by 6 · see citing works

RNA-Based Vaccines and Therapeutics Against Intracellular Pathogens

Kola, N. S., Patel, D., & Thakur, A. (2024) · Methods in molecular biology · doi:10.1007/978-1-0716-3890-3_21 · Cited by 6 · see citing works

Enhancing broadly neutralising antibody suppression of HIV by immune modulation and vaccination

Nel, C., & Frater, J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1478703 · Cited by 8 · see citing works

RNA-lipid nanoparticle therapeutics for women’s health

Nomani, A., Saraswat, A. L., Zhang, Y., Parenky, A. C., Kuo, C.-T. J., Brown, H., Hartford, S. A., Rayaprolu, B. M., Bhalla, A. S. B., & Shameem, M. (2025) · Frontiers in Nanotechnology · doi:10.3389/fnano.2025.1475969 · Cited by 6 · see citing works

Pre-clinical evaluation of mRNA-lipid nanoparticles’ potency and toxicity: current practices and future directions

Muzard, C., Séguin, J., Bonnefoy, J., Salkini, N., Serra, V. A., Alhareth, K., Lemdani, K., & Mignet, N. (2025) · In vitro models · doi:10.1007/s44164-025-00096-5 · Cited by 4 · see citing works

Safety and efficacy of RNA vaccines: State of the art

Blagov, A. V., Bukaeva, A. A., Makarov, V. V., & Bochkaeva, Z. (2021) · Medical Immunology (Russia) · doi:10.15789/1563-0625-sae-2320 · Cited by 4 · see citing works

A tumor-selective mRNA system enables precision cancer treatment

Żak, M. M., Yoo, J., Utrero‐Rico, A., Walter, W., Mainkar, G., Adjmi, M., Kurian, A. A., Rahaman, A., Lozano‐Ojalvo, D., Ochando, J., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.11.015 · Cited by 4 · see citing works

Vaccine-Induced, High-Magnitude HIV Env-Specific Antibodies with Fc-Mediated Effector Functions Are Insufficient to Protect Infant Rhesus Macaques against Oral SHIV Infection

Curtis, A. D., Saha, P. T., Dennis, M. L., Berendam, S. J., Ramasubramanian, P., Cross, K., Alam, S. M., Ferrari, G., Kozlowski, P. A., Fouda, G. G., et al. (2022) · mSphere · doi:10.1128/msphere.00839-21 · Cited by 3 · see citing works

A Historical Overview on mRNA Vaccine Development

Verbeke, R., Cheng, M. H. Y., & Cullis, P. R. (2024) · Wiley eBooks · doi:10.1002/9783527838394.ch1 · Cited by 5 · see citing works

Applications of advances in mRNA-based platforms as therapeutics and diagnostics in reproductive technologies

Bafleh, W. S., Abdulsamad, H. M. R., Al-Qaraghuli, S. M., Khatib, R. Y. E., Elbahrawi, R. T., Abdukadir, A. M., Alsawae, S. M., Dimassi, Z., Hamdan, H., & Kashir, J. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1198848 · Cited by 2 · see citing works

Human Immunodeficiency Virus Vaccine

Graciaa, D. S., Walsh, S. R., & Rouphael, N. (2024) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2024.04.004 · Cited by 3 · see citing works

Funding Strategies to Foster Enabling Basic Science Research in the Development of an HIV Vaccine

Shapiro, S. Z. (2025) · Current HIV Research · doi:10.2174/011570162x360804250527065110 · Cited by 2 · see citing works

Opportunities and challenges in achieving a functional cure for HIV

Zhang, W., Zhou, M., Chen, J., He, Y., & Li, L. (2025) · Infectious Diseases & Immunity · doi:10.1097/id9.0000000000000175 · Cited by 1 · see citing works

mRNA vaccines for viral diseases: mechanism, advances, and future perspective

Chakraborty, B., & Singh, T. (2026) · Molecular Biology Reports · doi:10.1007/s11033-026-11856-1 · Cited by 1 · see citing works

Adjuvants, the Elephant in the Room for RNA Vaccines

D’haese, S., den Roover, S., & Aerts, J. L. (2022) · RNA technologies · doi:10.1007/978-3-031-08415-7_12 · Cited by 1 · see citing works

Nanotechnology in vaccines and personalized medicine

Azevedo, M. S. P., & Patri, A. K. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-824010-6.00043-5 · Cited by 1 · see citing works

RNA therapeutics for infectious diseases

Tu, L. M. T. P. P. L. M., Pham, T. T. D., & Than, V. T. (2024) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2024.01.002 · Cited by 1 · see citing works

Nanotechnology: New frontiers in anti-HIV therapy

Jampílek, J., & Kráľová, K. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-99596-2.00011-x · Cited by 1 · see citing works

mRNA Vaccines for HIV‐1

Lusso, P. (2024) · Wiley eBooks · doi:10.1002/9783527838394.ch9 · Cited by 1 · see citing works

Comparison candidate Tick-borne encephalitis virus vaccines based on mRNA, adenovirus serotype 25 and chimera of YFV vaccine strainPreprint

Kuznetsova, N. A., Gushchin, V. А., Marchuk, E. V., Siniavin, A. E., Kleymenov, D. A., Nikiforova, M. A., Zubkova, O. V., Popova, O., Викторовна, В. И., Ozharovskaia, T. A., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.01.16.633390 · Cited by 1 · see citing works

Multivalent Human Cytomegalovirus Glycoprotein B Nucleoside-Modified mRNA Vaccines Demonstrate a Greater Breadth in T cell but not Antibody ResponsesPreprint

Wang, H.-Y., Li, L., Nelson, C. S., Barfield, R., Valencia, S. M., Chan, C. C. W., Muramatsu, H., Lin, P. J. C., Pardi, N., An, Z., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.11.23.517695

Tracing the recent updates on vaccination approaches and significant adjuvants being developed against HIV

Malik, S., Muhammad, K., Aslam, S. M., & Waheed, Y. (2023) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2023.2182771

WITHDRAWN: Immunogenicity of a cold-chain friendly and long-term stable HIV multi-epitope protease cleavage sites (MEPCS)-mRNA-LNP vaccine.Preprint

Mandal, S., Ghosh, J. S., Lohani, S., Zhao, M., Cheng, Y., Luo, M., & Li, Q. (2023) · Research Square · doi:10.21203/rs.3.rs-2790997/v1

Peptide and m-RNA Vaccines: Peculiarities of Immunogenicity and Protective Effect

Stepanova, T. F., Trotsenko, O. E., Bakshtanovskaya, I. V., Анатольевна, Б. Е., & Stepanova, K. B. (2025) · Epidemiology and Vaccinal Prevention · doi:10.31631/2073-3046-2024-23-6-137-146

Generating an Anti-HIV Vaccine Using Nucleoside-modified mRNA Encoding Envelope

Pardi, N., Karikó, K., Hogan, M., Muramatsu, H., Hoxie, J. A., & Weissman, D. (2014) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2014.5554.abstract · Cited by 2 · see citing works

Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates

Saunders, K. O., Pardi, N., Parks, R., Santra, S., Mu, Z., Sutherland, L. L., Scearce, R. M., Barr, M., Eaton, A., Hernandez, G. E., et al. (2021) · npj Vaccines · doi:10.1038/s41541-021-00307-6 · Cited by 90 · see citing works

Evaluating the Immune Response in Rabbits to an Escalating Dose of mRNA-Based HIV-1 Env Immunogens

Ahmed, S., Parthasarathy, D., Picard, T. C., Matyas, G. R., Rao, M., & Herschhorn, A. (2025) · Vaccines · doi:10.3390/vaccines13111161 · Cited by 1 · see citing works

A multiclade env–gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques

Zhang, P., Narayanan, E., Liu, Q., Tsybovsky, Y., Boswell, K. L., Ding, S., Hu, Z., Follmann, D. A., Lin, Y., Miao, H., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01574-5 · Cited by 164 · see citing works

Enhancing anti-viral neutralization response to immunization with HIV-1 envelope glycoprotein immunogens

Ahmed, S., Parthasarathy, D., Newhall, R., Picard, T. C., Aback, M., Ratnapriya, S., Arndt, W. D., Vega‐Rodriguez, W., Kirk, N. M., Liang, Y., et al. (2023) · npj Vaccines · doi:10.1038/s41541-023-00774-z · Cited by 17 · see citing works